首页> 外国专利> 2-(5'-NITRO-2'-FURYL)-THIENO(2,3-D)PYRIDINESS AND SALTS THEREOF

2-(5'-NITRO-2'-FURYL)-THIENO(2,3-D)PYRIDINESS AND SALTS THEREOF

机译:2-(5'-硝基2'-FURYL)-噻吩并(2,3-D)的盐及其盐

摘要

1384161 Thiero[2,3-d]pyrimidines DR KARL THOMAE GmbH 7 April 1972 [10 April 1971] 16211/72 Heading C2C [Also in Division A5] 4 - Amino - 2 - (5 - nitro - 2 - furyl) - thieno- [2,3-d] pyrimidines (I) and the acid addition salts thereof in which R is amino, C 2-4 acylamino optionally substituted by one or two chlorine atoms, straight or branched chain mono-C 1-5 alkylamino, di-C 1-4 alkyl-amino in which the alkyl groups may be the same or different, straight or branched chain mono- or di-hydroxy-C 1-5 alkyl-amino in which the N atom is optionally substituted by C 1-4 alkyl, straight or branched chain di(hydroxy C 1-3 alkyl)amino, C 1-2 alkoxy- C 1-3 alkylamino, amino C 1-3 alkylamino N- acetyl-amino-alkylene-amino in which the alkylene chain contains 1 to 3 C atoms or a piperidino group optionally substituted by hydroxy and R1 and R 2 which may be the same or different are hydrogen, methyl or ethyl are prepared by (1) reacting a compound II in which Z is halogen or a free or substituted mercapto group with an amine RSP1/SP-H in which RSP1/SP is R with the exception of a C 2-4 acylamino group optionally substituted by one or two chlorine atoms (in the presence of a hydrogen halide binding agent when Z is halogen), (2) reacting compound (IV) with a nitrating agent such as preferably nitric acid or a mixture of nitric acid with sulphuric acid or acetic anhydride, (3) reacting compound (V) with a salt of nitrous acid in a polar solvent, (4) reacting compound (VI) with nitric acid or with a salt of nitric acid in the presence of a mineral acid or (5) acylating a compound (I) in which R is amino with an acid chloride or acid anhydride to form compound (I) in which R is C 2-4 acylamino optionally substituted by one or two chlorine atoms. In reactions (2) and (4) in which R contains free hydroxy or amino groups, these groups are protected prior to the reaction by acylation and the protecting groups are removed subsequently by action of an acid. Compound (I) in which R is aminoalkylamino may be prepared by acid hydrolysis of the corresponding compound (I) containing a N-acylaminoalkyleneamine radical. Compounds (II) in which Z is halogen are prepared by reacting 5-nitrofuran-2-imino carboxylic acid esters with 2-amino thiophene-3- carboxylic acid esters and halogenating the resulting 2-(5-nitro-2-furyl)-4-hydroxy-thieno- [2,3-d]pyrimidines with phosphorus oxychloride. Compounds (II) in which Z is a free or substituted mercapto group are prepared by reacting the corresponding 4-halo-thieno[2,3-d]pyrimidine with thiourea and optionally alkylating the resulting compound using a potassium alcoholate. 2 - (2 - Furyl) - 4 - hydroxy - thieno[2,3-d]- pyrimidine, prepared by the above cyclization reaction is halogenated to form the corresponding 4-halo compound which is either reacted (1) with an amine R-H to form compounds (IV) or (2) with bromine in the presence of a hydrogen halide binding agent and subsequently with an amine R-H to form compounds (V). Compounds (VI) are prepared by reaction of 5-carbalkoxyfuran-2-imino carboxylic acid ester with 2- amino thiophene 3-carboxylic acid ester; the resulting compound is halogenated, reacted with an amine R-H and saponified in the presence of an acid. Compounds (I) are active against bacteria, moulds and trichomonads and form with a suitable carrier a pharmaceutical composition which may be administered orally, parenterally, rectally, vaginally or topically. A dragee comprises 4 - (2 - hydroxy - ethylamino) - 2 - (5- vitro - 2 - furyl) thieno[2,3-d]pyrimidine and papaverine.
机译:1384161 Thiero [2,3-d]嘧啶DR KARL THOMAE GmbH 1972年4月7日[1971年4月10日]标题C2C [也在A5部门中] 4-氨基-2-(5-硝基-2-呋喃基)-硫杂-[2,3-d]嘧啶(I)及其酸加成盐,其中R是氨基,C 2-4酰基氨基任选被一个或两个氯原子取代,直链或支链的单-C 1-5烷基氨基,其中烷基可以相同或不同的二-C 1-4烷基-氨基,直链或支链的单或二羟基-C 1-5烷基-氨基,其中N原子可选地被C 1取代-4烷基,直链或支链二(羟基C 1-3烷基)氨基,C 1-2烷氧基-C 1-3烷基氨基,氨基C 1-3烷基氨基N-乙酰基-氨基-亚烷基-氨基链含有1-3个碳原子或任选被羟基取代的哌啶子基,R 1和R 2可以相同或不同,是氢,甲基或乙基,是通过(1)使Z为卤素或自由或苏用胺R 1 -H取代的巯基,其中R 1 是R,但C 2-4酰基氨基可选被一个或两个氯原子取代( (Z)为卤素时,在卤化氢粘合剂存在下),(2)使化合物(IV)与硝化剂,例如硝酸或硝酸与硫酸或乙酸酐的混合物反应,(3)使化合物(V)与极性溶剂中的亚硝酸盐,(4)使化合物(VI)与硝酸或在无机酸存在下与硝酸盐反应,或(5)将化合物(I)酰化。其中R是氨基与酰氯或酸酐形成化合物(Ⅰ),其中R是任选被一个或两个氯原子取代的C 2-4酰基氨基。在其中R包含游离羟基或氨基的反应(2)和(4)中,这些基团在反应之前通过酰化被保护,并且随后通过酸的作用除去保护基。可以通过酸水解含有N-酰基氨基亚烷基胺基团的相应化合物(I)来制备其中R是氨基烷基氨基的化合物(I)。 Z为卤素的化合物(II)是通过使5-硝基呋喃-2-亚氨基羧酸酯与2-氨基噻吩-3-羧酸酯反应并卤化所得的2-(5-硝基-2-呋喃基)-来制备的。 4-羟基-噻吩并[2,3-d]嘧啶与三氯氧化磷。通过使相应的4-卤代-噻吩并[2,3-d]嘧啶与硫脲反应,并任选地使用醇钾烷基化所得化合物,来制备其中Z为游离或取代的巯基的化合物(II)。通过上述环化反应制备的2-(2-呋喃基)-4-羟基-噻吩并[2,3-d]-嘧啶被卤化形成相应的4-卤代化合物,该化合物可与(1)胺RH反应在卤化氢粘合剂存在下与溴形成化合物(IV)或(2),然后与胺RH形成化合物(V)。化合物(Ⅵ)是通过使5-羧烷氧基呋喃-2-亚氨基羧酸酯与2-氨基噻吩3-羧酸酯反应而制得的。所得化合物被卤化,与胺R-H反应并在酸存在下皂化。化合物(Ⅰ)对细菌,霉菌和滴虫有活性,并与合适的载体形成药物组合物,该药物组合物可以口服,肠胃外,直肠,阴道或局部给药。糖衣丸包含4-(2-羟基-乙基氨基)-2-(5-体外-2-呋喃基)噻吩并[2,3-d]嘧啶和罂粟碱。

著录项

  • 公开/公告号PH10479A

    专利类型

  • 公开/公告日1977-05-11

    原文格式PDF

  • 申请/专利权人 BOEHRINGER INGELHEIM GMBH;

    申请/专利号PH19720013419

  • 发明设计人 WOITUN E;REUTER W;

    申请日1972-04-05

  • 分类号C07D211/00;

  • 国家 PH

  • 入库时间 2022-08-23 00:42:39

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号